Nestin expression throughout multistep pathogenesis of multiple myeloma
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
24329895
DOI
10.1111/bjh.12689
Knihovny.cz E-zdroje
- Klíčová slova
- flow cytometry, monoclonal gammopathy, multiple myeloma, nestin, stem cells,
- MeSH
- dospělí MeSH
- imunofenotypizace MeSH
- lidé středního věku MeSH
- lidé MeSH
- messenger RNA genetika MeSH
- mnohočetný myelom diagnóza imunologie metabolismus patologie MeSH
- monoklonální gamapatie nejasného významu metabolismus MeSH
- nádorové biomarkery biosyntéza genetika MeSH
- nádorové buňky kultivované MeSH
- nádorové proteiny biosyntéza genetika MeSH
- nestin biosyntéza genetika MeSH
- plazmocelulární leukemie metabolismus MeSH
- prognóza MeSH
- progrese nemoci MeSH
- recidiva MeSH
- RNA nádorová genetika MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- messenger RNA MeSH
- nádorové biomarkery MeSH
- nádorové proteiny MeSH
- nestin MeSH
- RNA nádorová MeSH
The stem cell marker nestin (NES) is found in dividing cells of developing and regenerating tissues. Upon terminal differentiation, NES expression is diminished but may be re-expressed following injury or in cancer. Surprisingly, we recently confirmed NES as a tumour-specific marker for mature CD138(+) 38(+) plasma cells (PC) in multiple myeloma (MM). The present study analysed NES expression throughout the spectrum of MM developmental stages, starting with individuals with no haematological malignancy, through monoclonal gammopathy of undetermined significance (MGUS) and MM to plasma cell leukaemia (PCL) and MM cell lines. NES was analysed in bone marrow PC of 163 MM, four PCL and nine MGUS patients, 10 individuals with no haematological malignancy and 6 myeloma cell lines (OPM-2, RPMI-8226, MOLP-8, U-266, EJM, NCI-H929) by flow cytometry and/or real-time polymerase chain reaction or immunochemistry. We observed a tendency of increased NES expression in parallel with disease progression. NES was evaluated as a reliable marker for accurate discrimination between MM patients and the control group. High NES levels were strongly associated with the presence of 1q21 gain. For the first time, NES was demonstrated to predict worse response to conventional therapy/novel agents. These results suggest that NES might become a useful clinical parameter with an important role in MM pathogenesis.
Citace poskytuje Crossref.org
Nestin as a marker of cancer stem cells
